Erin Cullefer
Acute Care · Columbus, GANPI 1316393382
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Actelion Pharmaceuticals US, Inc. accounts for 70.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $4,614 and has fallen 95.4% since, to $211 in 2025. Among acute care clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $50.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$5K
- Novartis$709
- Johnson & Johnson$326
- Medtronic$181
- AstraZeneca$129
- Esperion Therapeutics, Inc.$125
- plus $544 from 10 others
What the payments were for
- Consulting fees$3,17847%
- Travel & lodging$76711%
- Food & beverage$2,82242%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 28 | $4,752 |
| Novartis | 44 | $709 |
| Johnson & Johnson | 33 | $326 |
| Medtronic | 2 | $181 |
| AstraZeneca | 3 | $129 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Abbott | 2 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Pfizer | 5 | $72 |
| United Therapeutics Corporation | 5 | $70 |
| Boston Scientific | 3 | $59 |
| Inspire Medical Systems, Inc. | 1 | $39 |
| Boehringer Ingelheim | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Bayer | 1 | $20 |
| Cvrx, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,766 in reported general payments places this provider in the 95th percentile of 679 acute care providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 25 | $22,038 |
| EliquisApixaban | 17 | $9,709 |
| Rosuvastatin Calcium | 17 | $423 |
| Potassium Chloride | 14 | $409 |
| Metoprolol Succinate | 43 | $336 |
| Atorvastatin Calcium | 22 | $216 |
| Carvedilol | 14 | $112 |
| Hydralazine Hcl | 12 | $32 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $326 | $22,03825 claims |
| PfizerEliquis | $72 | $9,70917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 acute care providers in Georgia.
Other acute care in Columbus
- Sally WatkinsColumbus$8K
- Rachel WarburtonColumbus$4K
- Stephanie RobertsonColumbus$3K
- Darryl TurnerRinggold$21K
- Bryce CowgillCumming$16K
- Stacy CreelSavannah$15K
- Susan BeitzellAthens$13K
- Crystal KuhnCumming$12K
- Mark ClarkGainesville$10K
- Sarah WymanAtlanta$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.